Information Provided By:
Fly News Breaks for February 29, 2016
PMC
Feb 29, 2016 | 09:00 EDT
After PharMerica provided lower than expected fiscal 2016 EPS guidance, KeyBanc says that the 27% plunge in the stock was overdone. The firm thinks that the stock's valuation is compelling at current levels, and it notes that the company is diversifying its business away from the "challenged" LTC pharmacy business. KeyBanc trimmed its price target on the name to $32 from $39 but keeps an Overweight rating on the stock.
News For PMC From the Last 2 Days
There are no results for your query PMC
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.